Htut Thura W, Thein Kyaw Z, Lawrie Alastair, Tighe Jane, Preston Gavin
Department of Haematology, Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen UK.
Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA.
EJHaem. 2020 Jun 23;1(1):262-266. doi: 10.1002/jha2.46. eCollection 2020 Jul.
The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta-analysis of phase III randomized controlled trials (RCT) to determine the efficacy of daratumumab combination regimens. The relative risk for progression was significantly lower in daratumumab-treated cohorts (HR 0.46, 95% CI 0.38-0.55) and this was consistent across newly diagnosed and relapsed cases. No statistically significant improvement was identified in newly diagnosed patients with high-risk cytogenetics and this group remains a therapeutic challenge.
近年来，CD38单克隆抗体达雷妥尤单抗与标准骨髓瘤化疗方案联合使用的情况已得到广泛研究。我们对III期随机对照试验（RCT）进行了更新的荟萃分析，以确定达雷妥尤单抗联合方案的疗效。在接受达雷妥尤单抗治疗的队列中，疾病进展的相对风险显著降低（风险比0.46，95%置信区间0.38 - 0.55），这在新诊断和复发病例中都是一致的。在新诊断的高危细胞遗传学患者中未发现有统计学意义的改善，该组仍然是一个治疗挑战。
